.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Julphar
Mallinckrodt
Queensland Health
Chubb
Boehringer Ingelheim
Chinese Patent Office
US Army
Merck
Fish and Richardson

Generated: September 19, 2017

DrugPatentWatch Database Preview

Genentech Company Profile

« Back to Dashboard

What is the competitive landscape for GENENTECH, and when can generic versions of GENENTECH drugs launch?

GENENTECH has nine approved drugs.

There are twenty-four US patents protecting GENENTECH drugs.

There are two hundred and ninety-nine patent family members on GENENTECH drugs in forty-four countries.

Summary for Applicant: Genentech

Patents:24
Tradenames:10
Ingredients:6
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-001Dec 22, 1999DISCNNoNo► Subscribe► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
COTELLIC
cobimetinib fumarate
TABLET;ORAL206192-001Nov 10, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech
PROTROPIN
somatrem
INJECTABLE;INJECTION019107-002Oct 24, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech
ERIVEDGE
vismodegib
CAPSULE;ORAL203388-001Jan 30, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Genentech

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999► Subscribe► Subscribe
Genentech
PROTROPIN
somatrem
INJECTABLE;INJECTION019107-001Oct 17, 1985► Subscribe► Subscribe
Genentech
NUTROPIN
somatropin recombinant
INJECTABLE;INJECTION020168-002Nov 17, 1993► Subscribe► Subscribe
Genentech
NUTROPIN
somatropin recombinant
INJECTABLE;INJECTION020168-001Nov 17, 1993► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN AQ PEN
somatropin recombinant
INJECTABLE;INJECTION020522-002Apr 22, 2002► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Genentech

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,915,250Azetidines as MEK inhibitors for the treatment of proliferative diseases► Subscribe
7,867,516Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient► Subscribe
9,321,761Pyridyl inhibitors of hedgehog signalling► Subscribe
9,017,722Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genentech Drugs

Country Document Number Estimated Expiration
CroatiaP20110959► Subscribe
Hong Kong1145138► Subscribe
Hong Kong1217903► Subscribe
Eurasian Patent Organization201200559► Subscribe
Morocco29875► Subscribe
Portugal1789390► Subscribe
JapanWO2002060446► Subscribe
Canada2709997► Subscribe
Peru13482012► Subscribe
Canada2667654► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genentech Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0 12-2013Slovakia► SubscribePRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848/001 20130712
2016 00021Denmark► SubscribePRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124
2013000074Germany► SubscribePRODUCT NAME: ERIVEDGE - VISMODEGIB; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: SCHWEIZ IKS-NR. 62497 20130530
2016016Lithuania► SubscribePRODUCT NAME: KOBIMETINIBAS; REGISTRATION NO/DATE: EU/1/15/1048 20151120
0809Netherlands► SubscribePRODUCT NAME: COBIMETINIBI, DESGEWENST FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN DAARVAN, IN HET BIJZONDER COBIMETINIB HEMIFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1048 20151124
14/002Ireland► SubscribePRODUCT NAME: ERIVEDGE-VISMODEGIB OR A SALT OR SOLVATE THEREOF; NAT REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION NO/DATE: 62497 01 20130530
C0021France► SubscribePRODUCT NAME: COBIMETINIB,OPTIONNELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE,NOTAMMENT SES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'HEMIFUMARATE DE COBIMETINIB; REGISTRATION NO/DATE: EU/1/15/1048 20151124
0130027 00083Estonia► SubscribePRODUCT NAME: VISMODEGIIB;REG NO/DATE: K(2013)4550 (LOPLIK) 12.07.2013
C0002France► SubscribePRODUCT NAME: VISMODEGIB AINSI QUE SES SELS ET SOLVATES; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: IKS 62497 20130530
90057-6Sweden► SubscribePRODUCT NAME: VISMODEGIB OCH SOLVAT DAERAV; NAT. REG. NO/DATE: EU/1/13/848 20130712; FIRST REG.: CH IKS-NR 62497 20130530
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
McKesson
Fuji
QuintilesIMS
Medtronic
Fish and Richardson
Covington
Accenture
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot